[The influence of 3 weeks therapy with continuous positive airway pressure on serum leptin and homocysteine concentration in patients with obstructive sleep apnea syndrome].
Obstructive sleep apnea (OSA) is one of the most often sleep disturbance. Not treated patients have 2-3 times more risk for death because of the cardiovascular diseases. Leptin and homocysteine are the risk factors for cardiovascular diseases. Treatment by nCPAP has positive influence for health care and reduction of hypertension in this group. The aim of this study was to evaluate an effect of 3 weeks nCPAP therapy on a serum leptin and homocysteine concentrations in patients with OSA.


METHODS
The study group consisted of 48 male patients in the age x=51,2?7,5 years old, OSA was diagnosed by polisomnographic study The leptin concentration was evaluated by RIA methods (HUMAN LEPTIN RIA KIT), the homocysteine concentration was evaluated byAxis Homocysteine EIA test. Patients were treated by nCPAP during 3 weeks. Only 29 patients were effectively treated for this time. The compliance was: 5.07 +/-1.81 h


RESULTS
In the group of 29 patients the serum leptin and homocysteine concentration before and after treatment were 11,05+/-5,59 ng/mL vs 11,07+/-7,16 ng/mL i 10,98+/-2,79 micromol/L vs 10,34+/-2,99 micromol/L. In the all study group the statistical important correlation between leptin and AHI, mean and minimal saturation overnight, fibrinogene concentration, BMI, WHR, waist circumference, heart rate and between homocysteine and heart rate were observed.


CONCLUSIONS
3 weeks therapy does not have any effect on leptin and homocysteine concentrations in the studied group of patients with OSA. Serum leptin concentration correlates with AHI, TMB90, as well as with mean and minimal saturation during a sleep. This indicates a potentially higher risk of cardiovascular diseases in the studied group.
Rubinsztajn
Renata
R
Katedra i Klinika Chorób Wewnetrznych, Pneumonologii i Alergologii AM w Warszawie. rrubin@amwaw.edu.pl
Kumor
Marta
M
Byśkiniewicz
Krzysztof
K
Chazan
Ryszarda
R
D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood* / Q000175:diagnosis* / Q000209:etiology; D045422:Continuous Positive Airway Pressure / Q000009:adverse effects; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D017286:Polysomnography; D012307:Risk Factors; D020181:Sleep Apnea, Obstructive / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*
D015415:Biomarkers; D020738:Leptin; D006710:Homocysteine